GlassScriptPhysician profile
Michael David Kolman
NPI 1134757008
$605.94
in general payments reported to CMS, 2019-2025
13 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $42.88 · 2024: $161 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606 · Education: $0.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.55 |
| Education | $0.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $164.71 | 2024-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $97.50 | 2025 | |
| Calliditas Therapeutics US INC. | $77.85 | 2023-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $35.78 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $34.81 | 2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $32.11 | 2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $29.67 | 2025 | Farxiga |
| Merck Sharp & Dohme LLC | $28.35 | 2025 | Prevymis |
| Akebia Therapeutics INC | $27.18 | 2025 | Vafseo |
| Vantive US Healthcare LLC | $26.66 | 2025 | Renal - Pd |
| Novo Nordisk INC | $26.37 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $24.56 | 2023 | Acthar |
| Travere Therapeutics, INC. | $0.39 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kolman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.